Serum antithyroglobulin antibodies (sTgAb) affect the reliability of Tg measurement in patients with thyroid cancer. We compared the outcome of patients with detectable and undetectable sTgAb, stratified according to the initial risk of recurrence (RR); also the response to treatment in patients with detectable sTgAb treated with total thyroidectomy (TT) with and without radioiodine remnant ablation (RA) and the sTgAb trend in the long-term follow-up according to the initial response.
We included 432 patients submitted to TT, with or without RA; 106 patients had detectable sTgAb levels. Median follow-up was 53 months.
There were no statistically significant differences considering presentation between negative or positive sTgAb subjects. The frequency of structural incomplete response (SIR) in low, intermediate, and high RR was similar. Undetectable sTgAb in patients was achieved in a median of 16 months in ablated patients compared with 11 months in those without RA (p = 0.0232). Patients without RA had a higher rate of undetectable sTgAb during the first 12 months. A SIR was observed in 3% of patients with declining sTgAb, in 19% of those with stable levels, and in 43% with increasing sTgAb (p = 0.004). The status of no evidence of disease was achieved more frequently in patients with initial sTgAb levels < 200 mUI/l, independently of the initial RR.
There was no impact of sTgAb on the initial clinical presentation and the response to therapy in low-risk patients treated with or without RA. sTgAb trend is more useful than an absolute value to predict a SIR.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 83, 2638–2648 (1998)
R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, G. Omry, J.A. Fagin, A. Shaha, Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010)
M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165, 441–446 (2011)
F. Pitoia, F. Jerkovich, C. Urciuoli, A. Schmidt, E. Abelleira, F. Bueno, G. Cross, R.M. Tuttle, Implementing the modified 2009 American Thyroid Association risk stratification system in thyroid cancer patients with low and intermediate risk of recurrence. Thyroid 25, 1235–1242 (2015)
B.R. Haugen, E.K. Alexander, K.C. Bible, G. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2015)
C. Durante, T. Montesano, M. Attard, M. Torlontano, F. Monzani, G. Costante, D. Meringolo, M. Ferdeghini, S. Tumino, L. Lamartina, A. Paciaroni, M. Massa, L. Giacomelli, G. Ronga, S. Filetti, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J. Clin. Endocrinol. Metab. 97, 2748–2753 (2012)
L. Kashat, S. Orlov, D. Orlov, J. Assi, F. Salari, P.G: Walfish, Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine. Endocrine 54, 460–466 (2016)
J.K. Chung, Y.J. Park, T.Y. Kim, Y. So, S.K. Kim, D.J. Park, D.S. Lee, M.C. Lee, B.Y. Cho, Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin. Endocrinol. 57, 215–221 (2002)
S. Mariotti, G. Barbesino, P. Caturegli, M. Marino, L. Manetti, F. Pacini, R. Centoni, A. Pinchera, Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? J. Clin. Endocrinol. Metab. 80, 468–472 (1995)
C.A. Spencer, L.M. Bergoglio, M. Kazarosyan, S. Fatemi, J.S. LoPresti, Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90, 5566–5575 (2005)
C. Spencer, I. Petrovic, S. Fatemi, Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 1283–1291 (2011)
F. Latrofa, D. Ricci, L. Montanelli, R. Rocchi, P. Piaggi, E. Sisti, L. Grasso, F. Basolo, C. Ugolini, A. Pinchera, P. Vitti, Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. J. Clin. Endocrinol. Metab. 97, 2380–2387 (2012)
F. Pacini, S. Mariotti, N. Formica, R. Elisei, S. Anelli, E. Capotorti, A. Pinchera, Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol. 119, 373–380 (1988)
E. Fiore, T. Rago, F. Latrofa, M.A. Provenzale, P. Piaggi, A. Delitala, M. Scutari, F. Basolo, G. Di Coscio, L. Grasso, A. Pinchera, P. Vitti, Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr. Relat. Cancer 18, 429–437 (2011)
F. Latrofa, D. Ricci, E. Sisti, P. Piaggi, C. Nencetti, M. Marino, P. Vitti, Significance of low levels of thyroglobulin autoantibodies associated with undetectable thyroglobulin after thyroidectomy for differentiated thyroid carcinoma. Thyroid 26, 798–806 (2016)
C. Spencer, I. Petrovic, S. Fatemi, J. LoPresti, Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J. Clin. Endocrinol. Metab. 99, 4589–4599 (2014)
F.A. Verburg, M. Luster, C. Cupini, L. Chiovato, L. Duntas, R. Elisei, U. Feldt-Rasmussen, H. Rimmele, E. Seregni, J.W. Smit, C. Theimer, L. Giovanella, Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid 23, 1211–1225 (2013)
L. Chiovato, F. Latrofa, L.E. Braverman, F. Pacini, M. Capezzone, L. Masserini, L. Grasso, A. Pinchera, Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. 139, 346–351 (2003)
W.G. Kim, J.H. Yoon, W.B. Kim, T.Y. Kim, E.Y. Kim, J.M. Kim, J.S. Ryu, G. Gong, S.J. Hong, Y.K. Shong, Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 93, 4683–4689 (2008)
Y. Tsushima, A. Miyauchi, Y. Ito, T. Kudo, H. Masuoka, T. Yabuta, M. Fukushima, M. Kihara, T. Higashiyama, Y. Takamura, K. Kobayashi, A. Miya, T. Kikumori, T. Imai, T. Kiuchi, Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients. Endocr. J. 60, 871–876 (2013)
R. Gorges, M. Maniecki, W. Jentzen, S.N. Sheu, K. Mann, A. Bockisch, O.E. Janssen, Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur. J. Endocrinol. 153, 49–55 (2005)
D. Thomas, V. Liakos, E. Vassiliou, F. Hatzimarkou, A. Tsatsoulis, P. Kaldrimides, Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation. J. Endocrinol. Investig. 30, 173–180 (2007)
K.C. Loh, F.S. Greenspan, F. Dong, T.R. Miller, P.P. Yeo, Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 84, 458–463 (1999)
B. Singh, A.R. Shaha, H. Trivedi, J.F. Carew, A. Poluri, J.P. Shah, Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 126, 1070–1076 (1999)
E. Kebebew, P.A. Treseler, P.H. Ituarte, O.H. Clark, Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J. Surg. 25, 632–637 (2001)
K. Kashima, S. Yokoyama, S. Noguchi, N. Murakami, H. Yamashita, S. Watanabe, S. Uchino, M. Toda, A. Sasaki, T. Daa, I. Nakayama, Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8, 197–202 (1998)
C. Ugolini, F. Basolo, A. Proietti, P. Vitti, R. Elisei, P. Miccoli, A. Toniolo, Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid 17, 389–393 (2007)
M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup,J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer (Eds), AJCC Cancer Staging Manual, 8th edn. (Springer, New York, 2017)
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)
A. Kumar, D.H. Shah, U. Shrihari, S.R. Dandekar, U. Vijayan, S.M. Sharma, Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid 4, 199–202 (1994)
S.L. Souza, L.V. Montalli Da Assumpção, L.S. Ward, Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid 13, 491–495 (2003)
C.A. Spencer, M. Takeuchi, M. Kazarosyan, C.C. Wang, R.B. Guttler, P.A. Singer, S. Fatemi, J.S. LoPresti, J.T. Nicoloff, Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 1121–1127 (1998)
J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): NHANES III. J. Clin. Endocrinol. Metab. 87, 489–499 (2002)
U. Feldt-Rasmussen, A.K. Rasmussen, Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones 9, 109–117 (2010)
S.D. Larson, L.N. Jackson, T.S. Riall, T. Uchida, R.P. Thomas, S. Qiu, B.M. Evers, Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J. Am. Coll. Surg. 204, 764–775 (2007)
H.S. Kim, Y.J. Choi, J.S. Yun, Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis. Endocr. Pathol. 21, 149–153 (2010)
K.W. Kim, Y.J. Park, E.H. Kim, S.Y. Park, J. Park do, S.H. Ahn, J. Park do, H.C. Jang, B.Y. Cho, Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto’s thyroiditis. Head. Neck. 33, 691–695 (2011)
S. Gupta, A. Patel, A. Folstad, C. Fenton, C.A. Dinauer, R.M. Tuttle, R. Conran, G.L. Francis, Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J. Clin. Endocrinol. Metab. 86, 1346–1354 (2001)
E.Y. Kim, W.G. Kim, W.B. Kim, T.Y. Kim, J.M. Kim, J.S. Ryu, S.J. Hong, G. Gong, Y.K. Shong, Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin. Endocrinol. 71, 581–586 (2009)
F. Consorti, M. Loponte, F. Milazzo, L. Potasso, A. Antonaci, Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur. Surg. Res. 45, 333–337 (2010)
E.S. Kim, D.J. Lim, K.H. Baek, J.M. Lee, M.K. Kim, H.S. Kwon, K.H. Song, M.I. Kang, B.Y. Cha, K.W. Lee, H.Y. Son, Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 20, 885–891 (2010)
O. Yamada, A. Miyauchi, Y. Ito, A. Nakayama, T. Yabuta, H. Masuoka, M. Fukushima, T. Higashiyama, M. Kihara, K. Kobayashi, A. Miya, Changes in serum thyroglobulin antibody levels as a dynamic prognostic factor for early-phase recurrence of thyroglobulin antibody-positive papillary thyroid carcinoma after total thyroidectomy. Endocr. J. 61, 961–965 (2014)
A. Ernaga-Lorea, M.C. Hernandez-Morhain, E. Anda-Apinaniz, J.J. Pineda-Arribas, I. Migueliz-Bermejo, N. Eguilaz-Esparza, A. Irigaray-Echarri, Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma. Clin. Transl. Oncol. 20, 740–744 (2017)
M.K. Slifka, R. Antia, J.K. Whitmire, R. Ahmed, Humoral immunity due to long-lived plasma cells. Immunity 8, 363–372 (1998)
U. Feldt-Rasmussen, M. Blichert-Toft, C. Christiansen, J. Date, Serum thyroglobulin and its autoantibody following subtotal thyroid resection of Graves’ disease. Eur. J. Clin. Investig. 12, 203–208 (1982)
S.A. Polyzos, A.D. Anastasilakis, Alterations in serum thyroid related constituents after thyroid fine-needle biopsy: a systematic review. Thyroid 20, 265–271 (2010)
S. Benvenga, L. Bartolone, S. Squadrito, F. Trimarchi, Thyroid hormone autoantibodies elicited by diagnostic fine needle biopsy. J. Clin. Endocrinol. Metab. 82, 4217–4223 (1997)
U. Feldt-Rasmussen, K. Bech, J. Date, P.H. Petersen, K. Johansen, A prospective study of the differential changes in serum thyroglobulin and its autoantibodies during propylthiouracil or radioiodine therapy of patients with Graves’ disease. Acta Endocrinol. 99, 379–385 (1982)
I.G. Rubio, M.N. Silva, M. Knobel, R. Romão, R. Possato, E.M. Gebrin, C. Buchpiguel, G. Medeiros-Neto, Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin. J. Endocrinol. Investig. 30, 535–540 (2007)
J.H. Seo, S.W. Lee, B.C. Ahn, J. Lee, Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18) F-FDG PET/CT. Clin. Endocrinol. 72, 558–563 (2010)
A. Adil, R.A. Jafri, A. Waqar, S.A. Abbasi, A.H. Matiul-Haq Asghar, A. Jilani, I. Naz, Frequency and clinical importance of anti-Tg auto-antibodies (ATG). J. Coll. Physicians Surg. Pak. 13, 504–506 (2003)
Conflict of interest
The authors declare that they have no conflict of interest.
The study was approved by the Institutional Review Board.
Informed consent was obtained from all individual participants included in the study.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bueno, F., Falcone, M.G.G., Peñaloza, M.A. et al. Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer. Endocrine 67, 387–396 (2020). https://doi.org/10.1007/s12020-019-02112-7
- Thyroid cancer
- Antithyroglobulin antibodies
- Risk of recurrence
- Response to therapy